If you searched “MK-677 before and after,” you were probably hoping to see dramatic transformation photos, week-by-week body updates, or user testimonials. We are not going to show you any of those. Dosage Peptide is a research-use-only dosage reference, and staged “before and after” images are among the least reliable forms of evidence for any compound — lighting, hydration, pump, posing, and photo timing can manufacture a “result” that has nothing to do with the molecule. Instead, here is something more useful and more honest: what actual clinical studies of MK-677 (ibutamoren) measured, on what timeline, and where the data stops. This is a scientific summary, not medical advice, and nothing here describes an approved human therapy.
What the research shows over time
MK-677 (ibutamoren, formerly Merck’s MK-0677) is an orally active growth hormone (GH) secretagogue — a ghrelin-receptor mimetic that prompts the pituitary to release more of your own GH. The human data is genuinely clinical (multiple randomized controlled trials), but it measured hormones and body composition, not the kind of visible “transformation” the search term implies. Here is the documented time-course.
First days to weeks (hormonal changes). In a randomized, placebo-controlled dose-finding trial in healthy older adults, 25 mg/day raised mean 24-hour GH by roughly 97% within two weeks and pushed IGF-1 into the young-adult range by four weeks (Chapman et al., 1996). This hormonal shift is the most consistently reproduced effect and it appears quickly.
Weeks to a few months (body composition begins to shift). In obese men given 25 mg/day for eight weeks, IGF-1 rose about 40% and fat-free (lean) mass increased significantly — but total and visceral fat did not change significantly, and glucose tolerance worsened (Svensson et al., 1998). So even the positive body-composition signal is largely water and lean tissue, not fat loss.
Months to years (the largest, longest trial). The most informative study is a two-year, double-blind RCT in 65 healthy adults aged 60–81 (Nass et al., 2008). Over 12 months, fat-free mass rose by about 1.1 kg with MK-677 versus a 0.5 kg decline on placebo, and body weight increased about 2.7 kg. Crucially, that added lean mass did not translate into measurable gains in strength or physical function. A related agonist study in hemodialysis patients confirmed IGF-1 rose roughly 65% versus placebo (Campbell et al., 2018).
| Study (type) | Duration | What was measured |
|---|---|---|
| Chapman et al., 1996 (RCT, healthy elderly, clinical) | 2–4 weeks | 24-h GH up ~97%; IGF-1 restored to young-adult range; fasting glucose rose |
| Svensson et al., 1998 (RCT, obese men, clinical) | 8 weeks | IGF-1 up ~40%; fat-free mass up; total/visceral fat unchanged; glucose tolerance impaired |
| Nass et al., 2008 (2-yr RCT, older adults, clinical) | 12–24 months | Fat-free mass +1.1 kg vs −0.5 kg placebo; weight +2.7 kg; no strength/function gain |
| Cardaci et al., 2022 (single case report, recreational, anecdotal) | 5 weeks | Lean +3.1% but fat +15.4%; LDL +40%, HDL −36%; ALT +205%; testosterone suppressed |
Clinical vs. preclinical vs. anecdotal. The GH/IGF-1 and lean-mass findings above are clinical (human RCTs). The only published account resembling a bodybuilding “before and after” is a single-subject case report in which MK-677 was stacked with the SARM LGD-4033 (Cardaci et al., 2022) — a sample size of one, with the two drugs confounded, and it showed fat mass rising 15% alongside adverse lipid, liver, and testosterone changes. That is anecdotal, not proof of anything.
The Effects People Actually Notice First
The trial endpoints — GH, IGF-1, fat-free mass — are not what users talk about. Three other effects show up far earlier, and two of them are genuinely documented.
Sleep: the best-supported subjective effect
This one has real controlled data behind it, which is unusual. In a double-blind, placebo-controlled crossover study, seven days of bedtime MK-677 at 25 mg increased stage IV (deep) sleep duration by roughly 50% and REM sleep by more than 20% in young adults; in adults aged 65–71, REM sleep rose by nearly 50% and REM latency fell (Copinschi et al., 1997). It is a small study, but it is randomized, blinded, and it measured sleep architecture directly rather than asking people how they felt. Of everything attributed to MK-677, this is the claim standing on the firmest ground.
Appetite: expected, and highly variable
MK-677 mimics ghrelin — the hormone that signals hunger — so increased appetite is the mechanism working, not a side effect of it. Trials consistently recorded it (Nass et al., 2008). The magnitude differs enormously between individuals, which is exactly why it is reported as trivial by some people and as unmanageable by others. Nothing in the data predicts which one you would be.
Water retention: why the mirror changes before the muscle does
Growth hormone drives sodium and fluid retention, and the trials recorded it as transient mild swelling of the lower limbs and muscle pain (Nass et al., 2008; Chapman et al., 1996). This matters for reading “before and after” photos honestly: a meaningful share of the early weight and “fullness” is intracellular and extracellular water, not new contractile tissue — and it is the part that disappears fastest when dosing stops. A photo taken at week 4 is largely photographing fluid.
Is MK-677 a Peptide?
No. This comes up constantly and the answer is clean: MK-677 (ibutamoren) is a non-peptide spiropiperidine — a small orally active molecule designed to mimic ghrelin at the growth hormone secretagogue receptor. It is not built from amino acids, which is precisely why it survives digestion and works as a tablet, while true peptides like sermorelin or ipamorelin have to be injected. It is grouped with peptides because it belongs to the same functional family — GH secretagogues — not because of its chemistry. It is also not a SARM, despite being sold alongside them.
Realistic expectations
What the data does support: MK-677 reliably raises GH and IGF-1 and produces a modest increase in lean body mass and body weight, much of it intracellular water. What the data does not support: meaningful fat loss, or any gain in strength, power, or physical function — the largest trial specifically found none (Nass et al., 2008). Individual variation is large, and effects on appetite in particular differ widely between people. This is exactly why online “before and after” galleries are misleading for a research compound: they are unblinded, uncontrolled, self-selected (people rarely post non-results), frequently involve simultaneous training, diet changes, or other compounds, and can be staged in a single afternoon. None of that isolates what MK-677 did.
Safety & legal status
Documented safety signals from the trials are consistent and worth taking seriously: increased appetite, transient mild lower-limb edema and muscle pain, rising fasting glucose with reduced insulin sensitivity, and increased cortisol (Nass et al., 2008; Svensson et al., 1998; Chapman et al., 1996). The stacked case report additionally flagged sharply worsened cholesterol and elevated liver enzymes (Cardaci et al., 2022). On status: MK-677 has been studied in humans for Alzheimer’s disease, hip fracture recovery, and fatty liver, but it is not an approved drug for any indication — Merck’s Phase 2 Alzheimer’s program (512 participants) completed without leading to approval (ClinicalTrials.gov NCT00074529), and it remains investigational. It is sold and referenced here strictly as a research chemical, not a supplement or medicine, and growth-hormone secretagogues are prohibited in competitive sport.
Dosage reference
For research-context handling, reconstitution, and the exact figures used across published trials, see our MK-677 (Ibutamoren) dosage chart. To convert concentrations or plan a reconstitution volume, use our peptide dosage calculator. These references are provided for laboratory and educational purposes only and are not instructions for human use.
FAQ
Are there real, verified “before and after” photos of MK-677?
No credible ones. Published research reported body-composition measurements (lean mass, fat mass, weight), not transformation photos. The internet photos you’ll find are unverified, uncontrolled, and often involve training, diet, or additional compounds, so they cannot be attributed to MK-677.
How long until changes appear in studies?
Hormonal changes (GH, IGF-1) appear within days to two weeks (Chapman et al., 1996). Measurable lean-mass changes emerged over roughly 8 weeks to 12 months in trials (Svensson et al., 1998; Nass et al., 2008) — but again, without gains in strength or function.
Does MK-677 burn fat?
The clinical evidence does not show meaningful fat loss. Trials found lean mass and body weight rising while total and visceral fat stayed essentially unchanged (Svensson et al., 1998; Nass et al., 2008).
How much of the weight gain is water?
A substantial share, especially early. GH promotes fluid retention, and trials recorded transient limb swelling and muscle pain alongside the lean-mass increase (Nass et al., 2008; Chapman et al., 1996). Dual-energy scans count that fluid inside the “fat-free mass” figure, so a 1–3 kg rise on paper is not 1–3 kg of new muscle.
Does MK-677 improve sleep?
This is the best-evidenced subjective effect. A randomized, double-blind crossover study found roughly 50% more deep (stage IV) sleep and over 20% more REM sleep in young adults after seven days at 25 mg taken at bedtime, and nearly 50% more REM in older adults (Copinschi et al., 1997). The study was small, so treat the size of the effect cautiously — but the direction is supported by controlled data, unlike most claims in this space.
Does MK-677 shut down your natural growth hormone?
It works by amplifying your own pituitary’s pulsatile release rather than replacing it, which is the pharmacological argument for secretagogues over injected GH. What the trials did document is a rise in fasting glucose and reduced insulin sensitivity, plus increased cortisol in the long study (Nass et al., 2008) — so “works with your own system” should not be read as “metabolically free.”
Is MK-677 a peptide or a SARM?
Neither. It is a non-peptide spiropiperidine that acts on the ghrelin (growth hormone secretagogue) receptor, which is why it is orally active. It has no androgen-receptor activity, so it is not a SARM either, despite usually being sold on the same shelf.
References
- Nass R, et al. Ann Intern Med. 2008;149(9):601–11. DOI (PMID 18981485)
- Svensson J, et al. J Clin Endocrinol Metab. 1998;83(2):362–9. DOI (PMID 9467542)
- Chapman IM, et al. J Clin Endocrinol Metab. 1996;81(12):4249–57. DOI (PMID 8954023)
- Cardaci TD, et al. Exp Physiol. 2022;107(12):1467–1476. DOI (PMID 36303408)
- Copinschi G, et al. Neuroendocrinology. 1997;66(4):278–86. DOI (PMID 9349662)
- Campbell GA, et al. Nephrol Dial Transplant. 2018;33(3):523–30. DOI (PMID 28340044)
- ClinicalTrials.gov NCT00074529 (MK-0677 Phase 2, Alzheimer’s disease, n=512).
Research-use-only. This article summarizes published research for educational purposes and is not medical advice, and does not describe an approved product or claim any human therapeutic or cosmetic effect.
